Frampton James E, Perry Caroline M
Wolters Kluwer Health, Adis, Auckland, New Zealand.
Drugs. 2008;68(18):2683-707. doi: 10.2165/0003495-200868180-00011.
Ibandronate (ibandronic acid; Bonviva, Boniva), a nitrogen-containing bisphosphonate available in once-monthly oral and quarterly intravenous formulations for intermittent administration, has been approved for the treatment of osteoporosis in postmenopausal women in the EU, the US and many other countries worldwide. The once-monthly oral formulation has also been approved for the prevention of postmenopausal osteoporosis in the US. Ibandronate is an effective and generally well tolerated bisphosphonate that offers an alternative to other bisphosphonates as a first-line treatment for postmenopausal osteoporosis. It occupies a similar position with respect to the prevention of osteoporosis in postmenopausal women at risk for the disease. The once-monthly oral and quarterly intravenous dosage regimens have the potential to improve treatment adherence and persistence, and hence clinical outcomes, compared with more frequently administered oral bisphosphonates. Intravenous ibandronate may be particularly useful for postmenopausal osteoporotic women who are noncompliant with, or are unable to tolerate or receive, oral bisphosphonates. Thus, intermittent ibandronate extends the range of pharmacological therapies for the treatment and prevention of postmenopausal osteoporosis.
伊班膦酸盐（伊班膦酸；邦罗力，Bonviva）是一种含氮双膦酸盐，有每月一次口服和每季度一次静脉注射两种剂型用于间歇性给药，已在欧盟、美国和全球许多其他国家被批准用于治疗绝经后妇女的骨质疏松症。在美国，每月一次口服剂型还被批准用于预防绝经后骨质疏松症。伊班膦酸盐是一种有效且耐受性良好的双膦酸盐，可作为绝经后骨质疏松症一线治疗的其他双膦酸盐的替代药物。在预防有患骨质疏松症风险的绝经后妇女患骨质疏松症方面，它处于类似地位。与更频繁给药的口服双膦酸盐相比，每月一次口服和每季度一次静脉注射的给药方案有可能提高治疗依从性和持续性，从而改善临床疗效。静脉注射伊班膦酸盐对于不依从、不能耐受或无法接受口服双膦酸盐的绝经后骨质疏松症妇女可能特别有用。因此，间歇性伊班膦酸盐扩展了治疗和预防绝经后骨质疏松症的药物治疗范围。
